0 results found with selected filters. Please refine the filters. Redirecting to initial search..
Table "column sort" updates the order of the bars in the chart.
downloaded on: 2025/02/10 22:50:46
Strain |
Phenotype |
Conditions |
Study |
Experiment Name |
Sex |
Age |
# of Animals |
Value |
Units |
SEM |
SD |
Method |
Method Duration |
Post Insult Time Value |
Post Insult Time Unit |
Method Notes |
Clinical Measurement Notes |
Record ID |
Study ID |
BDIX/OrlCrl |
blood CD8 cell count |
DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) then 5-fluorouracil (100 mg/kg) (for 7 days) |
Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. |
CD8-positive T cell quantity |
male |
111 days-125 days |
18 |
0.69 |
x 10E6 cells/ml |
0.05 |
0.23 |
fluorescence-activated cell sorting method |
0.0 |
48 |
days |
two treatments |
fluorouracil 5-FU |
111101 |
3196 |
BDIX/OrlCrl |
blood CD8 cell count |
DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) and thymosin alpha-1 (200 ug/kg) (between 44 and 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) |
Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. |
CD8-positive T cell quantity |
male |
111 days-125 days |
21 |
2.1 |
x 10E6 cells/ml |
0.08 |
0.36 |
fluorescence-activated cell sorting method |
0.0 |
48 |
days |
two treatments |
fluorouracil 5-FU +IL-2+ Ta1 |
111105 |
3196 |
BDIX/OrlCrl |
blood CD8 cell count |
DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) |
Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. |
CD8-positive T cell quantity |
male |
111 days-125 days |
18 |
1.23 |
x 10E6 cells/ml |
0.05 |
0.23 |
fluorescence-activated cell sorting method |
0.0 |
48 |
days |
two treatments |
fluorouracil 5-FU +IL-2 |
111103 |
3196 |
BDIX/OrlCrl |
blood CD8 cell count |
DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) |
Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. |
CD8-positive T cell quantity |
male |
91 days-105 days |
21 |
2.0 |
x 10E6 cells/ml |
0.11 |
0.51 |
fluorescence-activated cell sorting method |
0.0 |
28 |
days |
one treatment |
fluorouracil 5-FU + IL2 +Ta1 |
111104 |
3196 |
BDIX/OrlCrl |
blood CD8 cell count |
DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) |
Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. |
CD8-positive T cell quantity |
male |
91 days-105 days |
18 |
0.43 |
x 10E6 cells/ml |
0.02 |
0.11 |
fluorescence-activated cell sorting method |
0.0 |
28 |
days |
one treatment |
fluorouracil 5-FU |
111100 |
3196 |
BDIX/OrlCrl |
blood CD8 cell count |
DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) |
Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. |
CD8-positive T cell quantity |
male |
91 days-105 days |
18 |
1.1 |
x 10E6 cells/ml |
0.02 |
0.09 |
fluorescence-activated cell sorting method |
0.0 |
28 |
days |
one treatment |
fluorouracil 5-FU + IL2 |
111102 |
3196 |
|